Fed. Circ. Judges Stuck On Drug Efficacy's Role In Patents
A Federal Circuit panel struggled Thursday to pin down where the line is between patent enablement on cancer drug patents and U.S. Food and Drug Administration standards, as a Pfizer unit...To view the full article, register now.
Already a subscriber? Click here to view full article